RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Pharmaceutical Industry

A collection of news and information related to Pharmaceutical Industry published by this site and its partners.

Top Pharmaceutical Industry Articles

Displaying items 89-99
  • Shire to buy specialty drugmaker NPS Pharma for $5.2 billion

    Irish drugmaker Shire PLC said Sunday it will pay $5.2 billion to acquire NPS Pharmaceuticals, which specializes in drugs for rare conditions. The acquisition will expand Shire's portfolio of specialty drugs, medications for niche diseases and...
  • Alexion Pharmaceuticals Names New CEO

    Alexion Pharmaceuticals Names New CEO
    Alexion Pharmaceuticals Inc. in Cheshire has named a new chief executive, David L. Hallal, to replace current CEO and company founder Dr. Leonard Bell, effective April 1. Bell will continue to serve as chairman of the board of directors, the company...
  • Baxter's 2014 earnings: 4th quarter beat expectations

    Baxter's 2014 earnings: 4th quarter beat expectations
    Baxter International, the Deerfield-based medical products and pharmaceutical company, reported full year 2014 earnings Thursday as well as fourth-quarter results. The company beat expectations in nearly every category. Here's how the quarter and year...
  • Walgreens Boots Alliance unveils new logo

    Walgreens Boots Alliance unveils new logo
    Walgreens Boots Alliance unveiled a new logo Friday, a sphere meant to look like a globe that is a corporate departure from the red W that has been a fixture at its U.S. drugstores for years. The logo for the Walgreens stores is not changing, the...
  • AbbVie will rely on arthritis staple, new HCV drug in 2015

    AbbVie will rely on arthritis staple, new HCV drug in 2015
    North Chicago-based AbbVie issued a strong outlook for 2015 on Thursday after the markets closed. The biopharmaceutical company that was spun off from Abbott Laboratories expects earnings per share between $3.99 and $4.19 in 2015. The company said...
  • Express Scripts, CVS Health Dropping Coverage For Many Brand-Name Drugs: Why?

    Express Scripts, which handles prescription-drug benefits for millions of people nationwide, is dropping coverage for 66 brand-name drugs in January in an effort to keep costs down. Rival CVS Health is dropping 95 drugs from its own list of covered drugs....
  • Gilead counters AbbVie with exclusive hepatitis C drug deal of its own

     Gilead counters AbbVie with exclusive hepatitis C drug deal of its own
    CVS Health announced Monday that it plans to make Gilead Sciences' hepatitis C drugs the exclusive option for most of its consumers starting Wednesday. The announcement comes two weeks after Express Scripts, the nation's largest manager of prescription...
  • Abbott ends 2014 'with good momentum'

    Abbott ends 2014 'with good momentum'
    Abbott Laboratories, a North Chicago-based pharmaceutical and health care products company, reported full year 2014 earnings on Thursday, as well as fourth-quarter results. Abbott performed well overall, with the year marked by sales and acquisitions....
  • Drugs expensive under plans sold on health exchange, survey finds

    Drugs expensive under plans sold on health exchange, survey finds
    The Affordable Care Act is not so affordable for many Marylanders, according to a new survey. The landmark law that was supposed to make insurance available to hundreds of thousands of people without coverage is costing Marylanders so much more in...
  • FDA issues new requirements to improve defibrillator safety

    FDA issues new requirements to improve defibrillator safety
    The Food and Drug Administration is requiring makers of heart-zapping defibrillators to submit more data on the emergency care devices after years of recalls and manufacturing problems. Regulators say companies must now submit new testing data on...
  • AbbVie's new hepatitis C treatment gets approval in EU

    AbbVie's new hepatitis C treatment gets approval in EU
    Drugmaker AbbVie Inc. said Monday that its new, all-pill hepatitis C combo treatment has been approved for patients in the 28 European Union member countries. The company said the European Commission granted marketing authorization for the combination...